| UniProt ID | ARF1_HUMAN | |
|---|---|---|
| UniProt AC | P84077 | |
| Protein Name | ADP-ribosylation factor 1 | |
| Gene Name | ARF1 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 181 | |
| Subcellular Localization |
Golgi apparatus . Cytoplasm, perinuclear region . Cell junction, synapse, synaptosome. Cell junction, synapse, postsynaptic cell membrane, postsynaptic density. Membrane Lipid-anchor . |
|
| Protein Description | GTP-binding protein that functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. Involved in protein trafficking among different compartments. Modulates vesicle budding and uncoating within the Golgi complex. Deactivation induces the redistribution of the entire Golgi complex to the endoplasmic reticulum, suggesting a crucial role in protein trafficking. In its GTP-bound form, its triggers the association with coat proteins with the Golgi membrane. The hydrolysis of ARF1-bound GTP, which is mediated by ARFGAPs proteins, is required for dissociation of coat proteins from Golgi membranes and vesicles. The GTP-bound form interacts with PICK1 to limit PICK1-mediated inhibition of Arp2/3 complex activity; the function is linked to AMPA receptor (AMPAR) trafficking, regulation of synaptic plasicity of excitatory synapses and spine shrinkage during long-term depression (LTD).. | |
| Protein Sequence | MGNIFANLFKGLFGKKEMRILMVGLDAAGKTTILYKLKLGEIVTTIPTIGFNVETVEYKNISFTVWDVGGQDKIRPLWRHYFQNTQGLIFVVDSNDRERVNEAREELMRMLAEDELRDAVLLVFANKQDLPNAMNAAEITDKLGLHSLRHRNWYIQATCATSGDGLYEGLDWLSNQLRNQK | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 2 | N-myristoyl glycine | ------MGNIFANLF ------CCCHHHHHH | 35.62 | - | |
| 2 | Myristoylation | ------MGNIFANLF ------CCCHHHHHH | 35.62 | 23535599 | |
| 2 | Acetylation | ------MGNIFANLF ------CCCHHHHHH | 35.62 | 19413330 | |
| 22 | Sulfoxidation | KKEMRILMVGLDAAG CCCEEEEEEEECCCC | 1.77 | 30846556 | |
| 35 | Phosphorylation | AGKTTILYKLKLGEI CCCEEEEEEEECCCE | 15.49 | - | |
| 36 | Acetylation | GKTTILYKLKLGEIV CCEEEEEEEECCCEE | 35.38 | 22647619 | |
| 36 | Ubiquitination | GKTTILYKLKLGEIV CCEEEEEEEECCCEE | 35.38 | - | |
| 38 | Ubiquitination | TTILYKLKLGEIVTT EEEEEEEECCCEEEE | 50.74 | 21906983 | |
| 58 | Phosphorylation | FNVETVEYKNISFTV EEEEEEEEEEEEEEE | 12.66 | - | |
| 62 | Phosphorylation | TVEYKNISFTVWDVG EEEEEEEEEEEEECC | 25.02 | 22199227 | |
| 64 | Phosphorylation | EYKNISFTVWDVGGQ EEEEEEEEEEECCCC | 17.56 | 20068231 | |
| 73 | Sumoylation | WDVGGQDKIRPLWRH EECCCCCCCHHHHHH | 32.50 | - | |
| 73 | Ubiquitination | WDVGGQDKIRPLWRH EECCCCCCCHHHHHH | 32.50 | 21906983 | |
| 81 | Phosphorylation | IRPLWRHYFQNTQGL CHHHHHHHHCCCCEE | 9.78 | 29759185 | |
| 85 | Phosphorylation | WRHYFQNTQGLIFVV HHHHHCCCCEEEEEE | 17.15 | 28152594 | |
| 110 | Sulfoxidation | AREELMRMLAEDELR HHHHHHHHHHHHHHH | 2.31 | 30846556 | |
| 117 | Methylation | MLAEDELRDAVLLVF HHHHHHHHHHHHHHE | 28.00 | - | |
| 127 | Ubiquitination | VLLVFANKQDLPNAM HHHHEECCCCCCCCC | 41.58 | 21906983 | |
| 134 | Sulfoxidation | KQDLPNAMNAAEITD CCCCCCCCCHHHHHH | 4.45 | 30846556 | |
| 140 | Phosphorylation | AMNAAEITDKLGLHS CCCHHHHHHHHCCHH | 20.70 | 20860994 | |
| 142 | Acetylation | NAAEITDKLGLHSLR CHHHHHHHHCCHHCC | 35.49 | 66698813 | |
| 142 | Ubiquitination | NAAEITDKLGLHSLR CHHHHHHHHCCHHCC | 35.49 | 21906983 | |
| 147 | Phosphorylation | TDKLGLHSLRHRNWY HHHHCCHHCCCCCEE | 31.94 | 23927012 | |
| 167 | Phosphorylation | ATSGDGLYEGLDWLS ECCCCCHHHHHHHHH | 17.30 | 20736484 |
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of ARF1_HUMAN !! | ||||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Myristoylation | |
| Reference | PubMed |
| "Strategy for comprehensive identification of human N-myristoylatedproteins using an insect cell-free protein synthesis system."; Suzuki T., Moriya K., Nagatoshi K., Ota Y., Ezure T., Ando E.,Tsunasawa S., Utsumi T.; Proteomics 10:1780-1793(2010). Cited for: MYRISTOYLATION AT GLY-2. | |
| Phosphorylation | |
| Reference | PubMed |
| "A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-147, AND MASSSPECTROMETRY. | |